ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance
ANI Pharmaceuticals, Inc. Generated record quarterly net revenues of $137.4 million, representing year-over-year growth of 28.7%, net income to common shareholders of $17.8 million, and GAAP diluted earnings per share of $0.82 Delivered record adjusted non-GAAP EBITDA of $37.6 million, and adjusted non-GAAP diluted earnings per share of $1.21 Rare Disease business delivered Q1 net